SII Gets DCGI Permission to Manufacture COVID-19 Vaccine Covishield

New Delhi: The Serum Institute of India (SII) has received the permission of the Drugs Controller General of India (DCGI) to manufacture its COVID-19 vaccine ‘Covishield’, according to reports.

The permission for manufacture of the vaccine was given after the DCGI approved the Oxford COVID-19 vaccine Covishield for restricted emergency use in the country against coronavirus.

The DCGI has also approved restricted use to Bharat Biotech’s indigenously-developed ‘Covaxin’.

Earlier on Sunday, the DCGI approved two COVID-19 vaccines – Oxford’s Covishield, which is manufactured by Serum Institute of India (SII), and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in India.

Comments are closed.